Toni Choueiri, MD

Dr Choueiri on Trials in Progress in Advanced Renal Cell Carcinoma

July 14th 2023

Toni K. Choueiri, MD, discusses ongoing trials in advanced renal cell carcinoma.

Dr Choueiri on the Investigation of ICI Continuation in Advanced RCC

June 28th 2023

Toni Choueiri, MD, discusses remaining questions associated with the role of immune checkpoint inhibitor continuation following progression on a prior checkpoint blockade in advanced renal cell carcinoma, and attempts to address them through continued research.

Dr Choueiri on the Results of the CONTACT-03 Trial in Metastatic RCC

June 12th 2023

Toni Choueiri, MD, discusses the results of the phase 3 CONTACT-03 trial (NCT04338269) of atezolizumab and cabozantinib in patients with metastatic renal cell carcinoma.

Breaking Down Treatment Developments in Breast and Genitourinary Cancers From ESMO 2022: Drs O'Shaughnessy and Choueiri

September 12th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr. Choueiri on the Future Examination of Adjuvant Pembrolizumab in RCC

August 19th 2022

Toni Choueiri, MD, discusses the future examination of adjuvant pembrolizumab in renal cell carcinoma.

Dr. Choueiri on the Use of Adjuvant Pembrolizumab in RCC

July 25th 2022

Toni Choueiri, MD, discusses the use of adjuvant pembrolizumab in renal cell carcinoma.

Dr. Choueiri on Next Steps for Pembrolizumab in RCC

April 19th 2022

Toni Choueiri, MD, discusses the next steps for the evaluation of pembrolizumab in the phase 3 KEYNOTE-564 trial (NCT03142334) in renal cell carcinoma.

Dr. Choueiri on the Design of KEYNOTE-564 in RCC

March 2nd 2022

Toni Choueiri, MD, discusses the design of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Dr. Choueiri on the Follow-Up Analysis of KEYNOTE-564 in RCC

February 19th 2022

Toni Choueiri, MD, discusses the 30-month follow-up analysis of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Dr. Choueiri on the CheckMate-9ER Exploratory Analysis in Advanced RCC

March 18th 2021

Toni K. Choueiri, MD, discusses results from an exploratory analysis of the phase 3 CheckMate-9ER trial in patients with advanced renal cell carcinoma.

Nivolumab/Cabozantinib Combo Joins RCC Lineup

February 19th 2021

Patients with metastatic renal cell carcinoma have a new frontline treatment alternative following FDA approval of the combination of nivolumab plus cabozantinib combination.

Dr. Choueiri on the Rationale for the COSMIC-313 Trial in Advanced RCC

November 7th 2020

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

Experience Using Cabozantinib And Nivolumab for Advanced RCC

October 15th 2020

Sequencing Therapies for Advanced Renal Cell Carcinoma

October 15th 2020

Impact of CheckMate 9ER on the Treatment of Advanced RCC

October 15th 2020

Data from the CheckMate 9ER Trial for Advanced RCC

October 15th 2020

Treatment Landscape of Advanced Renal Cell Carcinoma

October 15th 2020

Dr. Choueiri on the Significance of the CCC19 During the COVID-19 Crisis

August 14th 2020

Toni K. Choueiri, MD, discusses the significance of the COVID-19 and Cancer Consortium during the coronavirus disease 2019 pandemic.

Dr. Choueiri on the Impact of the COVID-19 Pandemic on Treatment in RCC

August 7th 2020

Toni K. Choueiri, MD, discusses the impact the coronavirus disease 2019 pandemic has had on diagnosing and treating patients with renal cell carcinoma.

Dr. Choueiri on Subsequent Combo Therapy After PD-1/PD-L1 Blockade in RCC

September 11th 2019

Toni Choueiri, MD, discusses what therapy to give patients with renal cell carcinoma after they have received a PD-1/PD-L1 blockade.